A5044490350- Streptococcal Infections and Treatments
- Immunotherapy and Immune Responses
- Neonatal and Maternal Infections
- Antimicrobial Resistance in Staphylococcus
- RNA Interference and Gene Delivery
- Immune Response and Inflammation
- Antimicrobial Peptides and Activities
- Monoclonal and Polyclonal Antibodies Research
- HIV Research and Treatment
- Malaria Research and Control
- Kawasaki Disease and Coronary Complications
- Influenza Virus Research Studies
- Advanced Drug Delivery Systems
- vaccines and immunoinformatics approaches
- Biochemical and Structural Characterization
- Pneumonia and Respiratory Infections
- Complement system in diseases
- Microbial infections and disease research
- Glycosylation and Glycoproteins Research
- Respiratory viral infections research
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Nanoparticles: synthesis and applications
- Inflammasome and immune disorders
- Toxin Mechanisms and Immunotoxins
Griffith University
2014-2023
National Institute on Drug Abuse
2023
The University of Queensland
2010-2014
Technische Universität Braunschweig
2005
Special delivery: An effective group A streptococci vaccine is formed from a delivery device consisting of well-defined dendritic structures with nanoscale dimensions (see picture). The are designed to display multiple copies the minimal B-cell epitopes, which were in optimal conformation on surface nanoparticles. nanoparticles can be administered without aid an adjuvant.
The vast majority of human pathogens colonize and invade at the mucosal surfaces. Preventing infection these sites via mucosally active vaccines is a promising rational approach for vaccine development. However, it only recently that stimulation local immunity surfaces has become primary objective in addition to inducing systemic immunity. This review describes formulations designed delivery nasal-associated lymphoid tissue, intranasal administration. association antigens with adjuvants...
Vaccination can provide a safe alternative to chemotherapy by using the body's natural defense mechanisms create potent immune response against tumor cells. Peptide-based therapeutic vaccines human papillomavirus (HPV)-related cancers are usually designed elicit cytotoxic T cell responses targeting HPV-16 E7 oncoprotein. However, peptides alone lack immunogenicity, and an additional adjuvant or external delivery system is required. In this study, we developed new polymer-peptide conjugates...
Streptococcus pyogenes (group A streptococcus, GAS) is a Gram-positive bacterial pathogen responsible for wide variety of diseases. To date, GAS vaccine development has focused primarily on the M-protein. The M-protein highly variable at amino (N)-terminus (determining serotype) but conserved carboxyl (C)-terminus. Previously 29 acid peptide (named J14) from region was identified as potential candidate. J14 capable eliciting protective antibodies that recognized many serotypes when...
To explore four-arm star poly(t-butyl)acrylate (P(t)BA)-peptide and linear P(t)BA-peptide conjugates as a vaccine-delivery system against Group A Streptococcus.P(t)BA nanoparticles bearing J14 peptide epitopes were prepared via alkyne-azide 1,3-dipolar cycloaddition 'click' reaction. The conjugated products self-assembled into small or large nanoparticles. These nanoparticle vaccine candidates evaluated in vivo J14-specific antibody titers assessed.Mice vaccinated with the able to produce...
Infection with group A streptococcus (GAS) can result in a number of diseases, some which are potentially life-threatening. The oral-nasal mucosa is primary site GAS infection, and mucosally active vaccine candidate could form the basis an antidisease transmission-blocking vaccine. In present study, peptide from M protein (J14) representing B cell epitope was incorporated alongside universal T helper Toll-like receptor 2 targeting lipid moiety to lipopeptide constructs. Through structure...
Overexpression of certain tumor-associated carbohydrate antigens (TACA) caused by malignant transformation offers promising targets to develop novel antitumor vaccines, provided the ability break their inherent low immunogenicity and overcome tolerance immune system. We designed, synthesized, immunologically evaluated a number fully synthetic new chimeric constructs incorporating cluster most common TACA (known as Tn antigen) covalently attached T-cell peptide epitopes derived from polio...
Aim: Utilize lipopeptide vaccine delivery system to develop a candidate against Group A Streptococcus. Materials & methods: Lipopeptides synthesized by solid-phase peptide synthesis-bearing carboxyl (C)-terminal and amino (N)-terminal Streptococcus epitopes. Nanoparticles formed were evaluated in vivo. Results: Immune responses induced mice without additional adjuvant. We demonstrated for the first time that incorporation of C-terminal epitope significantly enhanced N-terminal...
Mucosally active subunit vaccines are an unmet clinical need due to lack of licensed immunostimulants suitable for vaccine antigens. Here, we show that intranasal administration liposomes incorporating: the Streptococcus pyogenes peptide antigen, J8; diphtheria toxoid as a source T cell help; and immunostimulatory glycolipid, 3D(6-acyl) PHAD (PHAD), is able induce long-lived humoral cellular immunity. Mice genetically deficient in either mucosal antibodies or total protected against S....
Abstract The upper respiratory tract (URT) is the major entry site for human pathogens and strategies to activate this network could lead new vaccines capable of preventing infection with many pathogens. Group A streptococcus (GAS) infections, causing rheumatic fever, heart disease, invasive are responsible substantial morbidity mortality. We describe an innovative vaccine strategy induce mucosal antibodies significant magnitude against peptide antigens GAS using a novel biocompatible...
Globally, group A streptococcal infections are responsible for over 500,000 deaths per year. safe vaccine that does not induce autoimmune pathology and affords coverage most GAS serotypes is highly desired. We have previously demonstrated a based on the conserved M-protein epitope, J8 was immunogenic in pilot Phase I study. subsequently improved efficacy by incorporation of B-cell epitope from IL-8 protease, SpyCEP, which protected enhanced neutrophil ingress to site infection. now...
Immunological assessment of group A streptococcal (GAS) branched lipopeptides demonstrated the impact spatial arrangement vaccine components on both quality and quantity their immune responses. Each lipopeptide was composed three components: a GAS B-cell epitope (J14), universal CD4+ T-cell helper (P25), an immunostimulant lipid moiety that differs only in its arrangement. The best systemic responses were by featuring at C-terminus. However, this candidate did not achieve protection against...
Extralieferung: Ein effektiver Impfstoff gegen Gruppe-A-Streptokokken wird von einem Liefersystem gebildet, das aus genau definierten nanoskaligen dendritischen Strukturen besteht (siehe Bild). Die präsentieren mehrere Kopien der minimalen B-Zellepitope, die auf Oberfläche Nanopartikel optimale Konformation haben. können ohne Zusatz eines Hilfsmittel verabreicht werden. Detailed facts of importance to specialist readers are published as "Supporting Information". Such documents peer-reviewed,...
Chikungunya virus (CHIKV) is the causative pathogen of chikungunya fever, a mosquito-borne viral disease causing highly debilitating arthralgia that can persist for months and progress to chronic arthritis. Our previous studies have identified CHIKV live-attenuated vaccine candidate CHIKV-NoLS. Like most vaccines, attenuated replication CHIKV-NoLS has potential limit scalable production. To overcome production limits, as well other drawbacks we developed an in vivo liposome-RNA delivery...